Global Non-Hodgkin Lymphoma (NHL) Market Research Report: Forecast (2022-27)

Market Definition

Non-Hodgkin Lymphoma (NHL) is cancer that usually starts in the body's lymphatic system, wherein lymphocytes grow abnormally & develop tumors throughout the body. Although NHL mainly occurs in adults, children can get it too. The disease can be lethal if not treated effectively and, in turn, result in a shorter life span for patients. However, various clinical trials conducted by the leading biotechnological & pharmaceutical companies worldwide for new drug developments, particularly for the relapsed & refractory cases, have aided in improving the prognosis for people with Non-Hodgkin Lymphoma.

Market Insights

The Global Non-Hodgkin Lymphoma (NHL) Market is expected to grow at around 7.6% CAGR during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the rising prevalence of B-cell lymphoma worldwide and mounting side effects of chemotherapy treatment, which, in turn, is leading to substantial R&D investments in procuring novel drugs to cure NHL. Besides, rapid drug approvals for B-cell lymphoma treatment in both developed & emerging countries and the impressive pipeline of targeted therapies, coupled with the label expansion of currently available therapies for treating various subtypes of NHL, are also driving the market.

Non-Hodgkin Lymphoma is usually more observed across countries with high living standards. BCLs (B-cell lymphomas) account for the majority of NHL cases, whereas FL (Follicular lymphoma) & DLBCL (Diffuse Large B-Cell Lymphoma) are the most common indolent & aggressive subtypes of NHL, respectively. Patients with NHL often require aggressive & accurate modes of treatment due to no show of symptoms, which results in the diagnosis of the disease in advanced stages. 

There are different treatment options for NHL, which depend entirely on its subtype & stage. They may include chemotherapy, stem cell transplant, immunotherapy (Monoclonal Antibodies, Antibody-drug Conjugates, Immunomodulatory Drugs, & CAR T-cell therapy), targeted therapies, radiation therapy, & surgery. There are high unmet patient needs for the treatment of Non-Hodgkin Lymphoma, i.e., leading to the launch of promising therapeutic drugs, which will further augment the growth of the Global Non-Hodgkin Lymphoma (NHL) Market through 2027.

Market Segmentation

Based on Treatment:

• Surgery
• Stem Cell Transplant
• Chemotherapy
• Immunotherapy
  • Monoclonal Antibodies
  • Antibody-drug Conjugates
  • Immunomodulatory Drugs
  • CAR T-cell therapy
• Targeted Therapy
• Radiation Therapy

Among all treatments, monoclonal antibodies (mAbs) of immunotherapy accounted for the largest share in the Global Non-Hodgkin Lymphoma (NHL) Market owing to their outstanding mechanism of action. Highly specific mAbs are directed at lymphoma cells and used as the first-line treatment as well as for recurrence of certain forms of NHL. Monoclonal antibodies are highly versatile, more effective, & show relatively fewer side effects than other therapeutics, which makes them suitable for targeting different sub-categories of NHL. As a result, the leading pharma companies are increasing the indication of already available mAbs for other cancer categories in order to expand their global presence.

On the other hand, CAR T-cell therapy is emerging as the most promising treatment for many subtypes of Non-Hodgkin Lymphoma, owing to its high efficiency in treating NHL patients. However, researchers are working toward further improving its efficacy & speeding up the response rate.

Cytokine Release Syndrome (CRS) & neurotoxicity induced by CAR T-cell therapy can result in considerable morbidity in patients. Hence, targeted molecular therapies, antibody-drug compounds, checkpoint inhibitors, & T-cell engagers in combination with CAR-T cell treatment are being adopted to minimize the side effects while yielding positive outcomes in NHL treatment.

Recent Drug Approvals by FDA for Non-Hodgkin Lymphoma

• In May 2022, FDA granted accelerated approval to Kymriah, tisagenlecleucel, developed by Novartis Pharmaceuticals Corporation, for adult patients with relapsed or refractory FL (Follicular Lymphoma) post at least two lines of systemic therapy.
• In April 2022, the association approved Yescarta (axicabtagene ciloleucel), developed by Kite Pharma, Inc., for adults with LBCL (Large B-cell Lymphoma), i.e., refractory to or relapses within 12 months of first-line chemoimmunotherapy. The therapy is not indicated for patients with primary central nervous system lymphoma.
• In December 2021, Rituxan (rituximab), developed by Genentech, Inc., in combination with chemotherapy, got FDA-approved for previously untreated patients over six months & below 18 years with advanced stage CD20-positive DLBCL, BLL (Burkitt-like lymphoma), mature B-AL (B-cell Acute Leukemia), or BL (Burkitt lymphoma).

Regional Landscape

Geographically, the Global Non-Hodgkin Lymphoma (NHL) Market expands across:

• North America
• South America
• Europe
• Middle East & Africa
• Asia-Pacific

Of all regions globally, North America would continue its dominance in the Non-Hodgkin Lymphoma (NHL) Market during 2022-27, owing primarily to the well-established healthcare facilities, early adoption of advanced healthcare technologies, and the rising incidence of B-cell NHL. It, in turn, is leading to the burgeoning adoption of expensive therapeutics for the NHL treatment across the region and fueling the overall market growth.

On the other hand, Asia-Pacific is expected to register rapid market growth over the forecast years, owing to the rising prevalence of several forms of NHL and massive investments in developing robust healthcare infrastructure to cater to patient requirements. Several biopharma companies across the region are investing in developing novel drug therapies to meet the growing demand for NHL treatment. In addition, with the mounting consumer awareness about the disease and the increasing regulatory approvals for expensive therapeutics like KYMRIAH (tisagenlecleucel) in Japan, the overall growth of the Non-Hodgkin Lymphoma (NHL) Market would notably expand across Asia-Pacific through 2027.

Market Dynamics:

Key Driver: Mounting Incidence of B-Cell Lymphoma & Improved Prognosis using Advanced Therapeutics

The growing patient pool for blood cancers, especially B-cell lymphomas, i.e., instigating the need for better clinical & therapeutic patient outcomes in refractory or relapsed cases, is the prime aspect projected to drive the Global Non-Hodgkin Lymphoma (NHL) Market during 2022-27. Moreover, rigorous R&D activities in developing efficient therapeutics for Non-Hodgkin Lymphoma have led to an overall improved prognosis. It, in turn, is driving more individuals toward adopting advanced treatments, which further projects remunerative prospects for the global market over the forecast years.

Growth Restraint: Skyrocketing Cost of Advanced NHL Therapeutics

The high cost of treatments, like immunotherapy, which restricts a large number of patients from opting for the required treatments due to the unavailability of appropriate payment options, is the most prominent growth restraint for the Global Non-Hodgkin Lymphoma (NHL) Market during 2022-27.

Key Questions Answered in the Market Research Report:

1. What are the overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares) of the Global Non-Hodgkin Lymphoma (NHL) Market?
2. What are the region-wise industry size, growth drivers, and challenges?
3. What are the key innovations, opportunities, current & future trends, and regulations in the Global Non-Hodgkin Lymphoma (NHL) Market?
4. Who are the key competitors, their key strengths & weaknesses, and how do they perform in the Global Non-Hodgkin Lymphoma (NHL) Market based on the competitive benchmarking matrix?
5. What are the key results derived from surveys conducted during the Global Non-Hodgkin Lymphoma (NHL) Market study?